Nurix says Sanofi discontinues autoimmune disease drug program

What happened

Nurix said Sanofi will stop developing SAR448272, an experimental oral treatment for autoimmune and inflammatory diseases, after discontinuing an early-stage trial. Nurix said it does not expect future development, regulatory or commercial milestone payments, or royalties from the program.

Confirmed

Global impact / market context

The loss of possible milestone payments and royalties removes a potential future source of revenue for Nurix from this collaboration. That can reduce the expected financial value of the program, while payments and royalties from other drug candidates under the Sanofi agreement remain possible.

Analyst inference

Sanofi said the decision followed emerging non-clinical data that did not meet its criteria for continued development, and was not a broader judgment on STAT6 as a drug target. This distinction leaves uncertainty about the wider scientific potential, but does not restore payments tied to this program.

Confirmed

What to watch

1. Watch for Nurix’s next disclosures on the financial impact of losing this program’s payments and royalties, including any updated expectations for revenue or cash available. Analyst inference
2. Track progress of other drug candidates in the Sanofi collaboration, since Nurix said it remains eligible for milestone payments and royalties from those programs. Analyst inference
3. Look for further information from Sanofi about SAR448272’s discontinued development and the non-clinical data behind its decision, which may clarify the program’s prospects. Analyst inference

Evidence

• Original source link unavailable